Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hormone therapy after risk-reducing surgery in patients with BRCA1/BRCA2 mutation: evaluation of potential benefits and safety.

Revista da Associacao Medica Brasileira (1992) - 1 Aug 2020

Silva Filho Agnaldo Lopes da, Carvalho Gabriella Martins, Sena Larissa Cristelli de, Gomes Lívia Passini Guimarães, Valério Marcos Flávio Habib, Martins Raíssa Isabelle Leão, Cândido Eduardo Batista

Abstract excerpt

Women with mutations in the BRCA 1 and 2 genes are at increased risk for ovarian and breast cancer and therefore candidates for risk-reducing surgery, including salpingo-oophorectomy and mastectomy. Risk-reducing salpingo-oophorectomy (RRSO) is considered the most effective prophylactic measure for ovarian cancer prevention in this group of patients. This procedure involves loss of ovarian function and induced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Mastectomy

Share to Ovarian Neoplasms

Share to Ovariectomy

Share to Quality of Life

Share to Salpingo-oophorectomy

Source

Identifiers

PMID: 32935810
DOI: 10.1590/1806-9282.66.8.1134

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hormone therapy after risk-reducing surgery in patients with BRCA1/BRCA2 mutation: evaluation of potential benefits and safety.PMID 32935810Read ↗

Hormone replacement therapy in BRCA mutation carriers: how shall we do no harm?Semantic proximity Read ↗

Is Hormone Replacement Therapy Safe in Women With a BRCA Mutation?: A Systematic Review of the Contemporary Literature.Semantic proximity Read ↗

Hormonal management after risk-reducing surgery in BRCA-mutated triple-negative breast cancer survivors.Semantic proximity Read ↗

Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2.Semantic proximity Read ↗

Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should know.Semantic proximity Read ↗

BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations.Semantic proximity Read ↗

Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.Semantic proximity Read ↗

Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.Semantic proximity Read ↗

Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Hereditary Women's Cancer: Management and Risk-Reducing Surgery.Semantic proximity Read ↗

Short-term Impact of Hormone Replacement Therapy on Risk of Breast Cancer in BRCA Mutation Carriers: A Nationwide Study in South Korea.Semantic proximity Read ↗

The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.